{"filing":{"accession_number":"0000879169-26-000058","cik":"0000879169","ticker":"INCY","company_name":"INCYTE CORP","form":"8-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"incy-20260831.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000058/incy-20260831.htm"},"events":[{"id":30641,"run_id":28090,"accession_number":"0000879169-26-000058","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"Incyte has entered into a pricing agreement with CMS affecting access to Jakafi and Jakafi XR through state Medicaid programs and providing relief from future CMS pricing mandates (GUARD and GLOBE models). While the company states no material impact on 2026 guidance or future outlook, the agreement represents a material operational and strategic development affecting drug pricing, market access, and regulatory exposure for a major product line. This is a significant business arrangement that does not fit neatly into other categories but is clearly operational in nature.","company_name":"INCYTE CORP","ticker":"INCY","filing_date":"2026-08-31","form":"8-K","submitted_at":null,"items":[{"id":33293,"accession_number":"0000879169-26-000058","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Incyte has entered into a pricing agreement with CMS affecting access to Jakafi and Jakafi XR through state Medicaid programs and providing relief from future CMS pricing mandates (GUARD and GLOBE models). While the company states no material impact on 2026 guidance or future outlook, the agreement represents a material operational and strategic development affecting drug pricing, market access, and regulatory exposure for a major product line. This is a significant business arrangement that does not fit neatly into other categories but is clearly operational in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T20:33:51.764645+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33293,"accession_number":"0000879169-26-000058","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Incyte has entered into a pricing agreement with CMS affecting access to Jakafi and Jakafi XR through state Medicaid programs and providing relief from future CMS pricing mandates (GUARD and GLOBE models). While the company states no material impact on 2026 guidance or future outlook, the agreement represents a material operational and strategic development affecting drug pricing, market access, and regulatory exposure for a major product line. This is a significant business arrangement that does not fit neatly into other categories but is clearly operational in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T20:33:51.764645+00:00","company_name":"INCYTE CORP","ticker":"INCY","filing_date":"2026-08-31"}]}